Is Gujarat Kidney and Super Speciality the Best Stock in Its Sector? A Look at the Numbers
- September 25, 2026
- Posted by: Harsh Piplani
- Category: Market
Gujarat Kidney and Super Speciality CMP Rs 177 (25 Sep 2026). Market cap Rs 1,347 Cr. ROE 6.14%. P/E 80.59x versus Industry P/E 69.35x.
Quick Answer
Gujarat Kidney and Super Speciality is one of the names investors compare when screening the Healthcare sector, built on a 6.14% return on equity and a P/E of 80.59x against an Industry P/E of 69.35x. Whether Gujarat Kidney and Super Speciality is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Gujarat Kidney and Super Speciality the best stock in its sector? The stock trades on the NSE at Rs 177 as of 25 September 2026, within its 52-week range of Rs 98.36 to Rs 186.99. Gujarat Kidney And Super Speciality Ltd operates dialysis and kidney super-speciality centres across Gujarat.
Gujarat Kidney and Super Speciality sits in the Healthcare sector, and its 6.14% ROE and 80.59x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Gujarat Kidney and Super Speciality
Gujarat Kidney And Super Speciality Ltd operates dialysis and kidney super-speciality centres across Gujarat. It operates dialysis and kidney super-speciality centres across Gujarat, and the stock rose nearly 4 percent today on very heavy volume, trading near its fresh 52-week high. At a market capitalisation of Rs 1,347 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Gujarat Kidney and Super Speciality the Best Stock in Its Sector?
Gujarat Kidney and Super Speciality makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 6.14% ROE with a 80.59x P/E against the sector’s 69.35x Industry P/E. Gujarat Kidney and Super Speciality’s 80.59x P/E is above the 69.35x Industry P/E, a premium built on its specialised dialysis and kidney care network, though its 6.14% ROE is modest relative to the multiple, and today’s sharp move on heavy volume is worth investigating.
| Metric | Gujarat Kidney and Super Speciality |
|---|---|
| CMP (NSE) | Rs 177.16 |
| 52-Week High / Low | Rs 186.99 / Rs 98.36 |
| Market Cap | Rs 1,347 Cr |
| P/E (TTM) vs Industry P/E | 80.59x vs 69.35x |
| P/B | 5.33 |
| ROE | 6.14% |
| EPS (TTM) | Rs 2.12 |
| Dividend Yield | 0.00% |
| Debt to Equity | 0.12 |
Compare Gujarat Kidney and Super Speciality Against Other Healthcare Sector Stocks
How Gujarat Kidney and Super Speciality Compares Against Its Healthcare Sector Peers
The table below sets Gujarat Kidney and Super Speciality against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Gujarat Kidney and Super Speciality | 1,347 | 80.59 | 6.14% | 0.12 |
| GPT Healthcare | 1,321 | 27.95 | 15.67% | 0.34 |
| Dr. Agarwal’s Health Care | 15,908 | 85.92 | 6.58% | 0.53 |
| Peer average (2 companies) | – | 56.94 | 11.12% | 0.44 |
Against this peer set, Gujarat Kidney and Super Speciality’s 6.14% ROE is below the 11.12% peer average, and its P/E of 80.59x runs above the peer average of 56.94x. Gujarat Kidney and Super Speciality’s 80.59x P/E is above the 69.35x Industry P/E, a premium built on its specialised dialysis and kidney care network, though its 6.14% ROE is modest relative to the multiple, and today’s sharp move on heavy volume is worth investigating.
What Makes Gujarat Kidney and Super Speciality Worth Watching in Healthcare
- Low leverage: A debt to equity ratio of 0.12 is manageable for a dialysis and kidney care centre operator.
- Dialysis and kidney care network: Operating dialysis and kidney super-speciality centres across Gujarat gives Gujarat Kidney and Super Speciality a focused, specialised healthcare vertical.
- Strong single-day move on heavy volume: The stock rose nearly 4 percent today on volume well above its recent average, worth understanding before acting on the current price.
Gujarat Kidney and Super Speciality Valuation: Is It Justified?
Gujarat Kidney and Super Speciality’s 80.59x P/E is above the 69.35x Industry P/E, a premium built on its specialised dialysis and kidney care network, though its 6.14% ROE is modest relative to the multiple, and today’s sharp move on heavy volume is worth investigating. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is GM Breweries the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Gujarat Kidney and Super Speciality and other Healthcare sector stocks.
How to Track Gujarat Kidney and Super Speciality Before You Invest
Before deciding whether Gujarat Kidney and Super Speciality deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Gujarat Kidney and Super Speciality to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Gujarat Kidney and Super Speciality earns a place in the best stock in its sector conversation on the strength of a 6.14% ROE and a P/E of 80.59x against a 69.35x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Gujarat Kidney and Super Speciality the best stock in its sector?
Ans. Gujarat Kidney and Super Speciality has a 6.14% ROE and trades at 80.59x P/E against a 69.35x Industry P/E, and compares below the peer average ROE of 11.12% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Gujarat Kidney and Super Speciality?
Ans. Gujarat Kidney and Super Speciality was trading at Rs 177.16 on the NSE as of 25 September 2026, within its 52-week range of Rs 98.36 to Rs 186.99.
What sector does Gujarat Kidney and Super Speciality belong to?
Ans. Gujarat Kidney and Super Speciality is classified under the Healthcare sector on Univest.
How does Gujarat Kidney and Super Speciality compare to its sector peers on P/E?
Ans. Gujarat Kidney and Super Speciality’s P/E of 80.59x is above the 56.94x average of the 2 named peers compared in this article.
What is Gujarat Kidney and Super Speciality’s return on equity?
Ans. Gujarat Kidney and Super Speciality reported a return on equity of 6.14%, which is below the 11.12% average of its named peers in this comparison.
Should I invest in Gujarat Kidney and Super Speciality based on its sector position?
Ans. Gujarat Kidney and Super Speciality’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
